Sarepta Therapeutics Stock Plunges as Second Patient Dies Taking Its Drug

Sarepta Therapeutics (SRPT) shares plummeted nearly 50% after a second patient taking its Elevidys drug for Duchenne muscular dystrophy died of acute liver failure (ALF); the company has temporarily suspended Elevidys shipments for non-ambulatory patients and paused a study evaluating the drug's efficacy for older patients. Sarepta will convene an independent group of experts to consider an enhanced immunosuppression regimen for Elevidys, as acute liver injury was previously noted as a possible side effect of the treatment. The stock price has fallen to a nine-year low following the announcement.

Analysis

Sarepta Therapeutics (SRPT) shares experienced a catastrophic decline, plummeting nearly 50% to reach their lowest level in nine years, following the announcement of a second patient death due to acute liver failure (ALF) associated with its Duchenne muscular dystrophy drug, Elevidys. This event follows a similar patient death reported in March, which also negatively impacted the stock. In response to this latest fatality, Sarepta has taken immediate, significant actions: temporarily suspending Elevidys shipments for non-ambulatory Duchenne patients, pausing a clinical study evaluating the drug's efficacy in older ambulatory and non-ambulatory patients, and convening an independent panel of liver health and Duchenne experts to reassess and potentially enhance the immunosuppression regimen for Elevidys. The company had previously acknowledged acute liver injury as a possible side effect and was in the process of updating prescribing information. These developments cast serious doubt on the safety profile and future commercial viability of Elevidys, a critical asset for Sarepta, particularly within the non-ambulatory patient segment, and significantly heighten regulatory and market scrutiny.

Key Decisions for Investors

• Investors should brace for sustained high volatility and further potential downside in SRPT shares, reflecting the severe safety concerns for Elevidys and the stock's precipitous fall to a multi-year low.
• Closely monitor outcomes from the independent expert review on Elevidys' safety and immunosuppression protocols, alongside any forthcoming regulatory guidance or labeling changes from health authorities, as these will be crucial determinants of the drug's future market access and Sarepta's valuation.
• Re-evaluate exposure to Sarepta, considering the profound negative impact these events have on Elevidys' addressable market, particularly for non-ambulatory patients, and the uncertainty introduced by the paused clinical study for older patient populations.